CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
ppublish
Résumé
In MOG antibody-associated disease (MOGAD), relapse prevention and the treatment approach to refractory symptoms are unknown. We report a patient with refractory MOGAD treated with CD19-directed CAR T-cells. CD19-directed CAR T-cells (ARI-0001) were produced in-house by lentiviral transduction of autologous fresh leukapheresis and infused after a conventional lymphodepleting regimen. A 18-year-old man developed 2 episodes of myelitis associated with serum MOG-IgG, which were followed by 6 episodes of left optic neuritis (ON) and sustained the presence of MOG-IgG over 6 years despite multiple immunotherapies. After the sixth episode of ON, accompanied by severe residual visual deficits, CAR T-cell treatment was provided without complications. Follow-up of cell counts showed complete depletion of CD19 This clinical case shows that CD19-directed CAR T-cell therapy is well-tolerated and is a potential treatment for patients with refractory MOGAD. This provides Class IV evidence. It is a single observational study without controls.
Identifiants
pubmed: 39106426
doi: 10.1212/NXI.0000000000200292
doi:
Substances chimiques
Antigens, CD19
0
Myelin-Oligodendrocyte Glycoprotein
0
CD19 molecule, human
0
MOG protein, human
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM